189P An image-based deep learning prediction model for characterization of the drug tolerant persister cell state

Targeted therapies improve the clinical outcome of cancer treatment. However, in solid tumors a cancer cell subpopulation survives during initial therapy and evolves into drug tolerant persister cells (DTPs) that maintain a residual disease reservoir. Residual disease contributes to lethal tumor progression; identifying and eliminating DTPs could benefit future treatment paradigms. We have shown that Hippo pathway effector Yes Associated Protein-1 (YAP1), a transcriptional co-regulator, is activated in oncogene-driven cancers in response to targeted therapy and maintains the DTP phenotype.